To distinguish the therapeutic impact in the unmatched tumor model, we expressed and purified the unmatched tumor antigen OVA with a lipid moiety at the N-terminus and fused it with GM-CSF at the C-terminus (rlipo-OVA-MoGM, online supplemental figure S3). This evidence concerns the gene CSF2 and neoplasm.